B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases

Curr Rheumatol Rep. 2002 Aug;4(4):345-50. doi: 10.1007/s11926-002-0044-7.


The size of the known members of the tumor necrosis factor ligand and receptor superfamilies has burgeoned in the past few years. Among the novel tumor necrosis factor ligand and receptor superfamily members recently described is B lymphocyte stimulator (BLyS; Human Genome Sciences, Rockville, MD) protein. By virtue of its ability to promote B-cell survival, expansion, and differentiation, it likely plays an important contributory role in systemic lupus erythematosus pathogenesis and propagation. In addition, it may play a similar role in other systemic immune-based rheumatic diseases, and becomes a legitimate candidate target for antagonist biologic agents.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Animals
  • Arthritis, Rheumatoid / blood
  • Arthritis, Rheumatoid / diagnosis
  • B-Cell Activation Factor Receptor
  • Biomarkers, Tumor / analysis*
  • Female
  • HIV Infections / blood
  • HIV Infections / diagnosis
  • Humans
  • Lupus Erythematosus, Systemic / blood
  • Lupus Erythematosus, Systemic / diagnosis*
  • Male
  • Membrane Proteins*
  • Mice
  • Prognosis
  • Protein Binding
  • Receptors, Tumor Necrosis Factor / analysis
  • Receptors, Tumor Necrosis Factor / metabolism*
  • Sensitivity and Specificity
  • T-Lymphocytes / physiology
  • Tumor Necrosis Factor-alpha / analysis*


  • B-Cell Activation Factor Receptor
  • BLyS receptor
  • Biomarkers, Tumor
  • Membrane Proteins
  • Receptors, Tumor Necrosis Factor
  • TNFRSF13C protein, human
  • Tnfrsf13c protein, mouse
  • Tumor Necrosis Factor-alpha